Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in Peripheral Artery Disease
NCT05009862Phase 4Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Apr 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rivaroxaban in peripheral artery disease (PAD) (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoints: Flow-mediated dilation at 37 days and Endogenous PAR-1 activation at 37 days. Started Apr 2022; status: completed.
02
Drugs
rivaroxaban
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT05009862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009862.